Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 11/20 | 0.38 |
| ▸ | F7 | P08709 | 11/20 | 0.38 |
| ▸ | F3 | P13726 | 11/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701002 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BF2F7F3 | |
| Hydrochloric Acid SCHEMBL6703865 | 0.89 | ITGB3 (0.42) | ITGB3ITGA2BF2F7F3 | |
| Hydrochloric Acid SCHEMBL6703856 | 0.89 | ITGB3 (0.42) | ITGB3ITGA2BF2F7F3 | |
| SCHEMBL7440166 | 0.86 | ITGB3 (0.49) | ITGB3ITGA2BF2F7F3 | |
| SCHEMBL7440145 | 0.86 | ITGB3 (0.49) | ITGB3ITGA2BF2F7F3 | |
| SCHEMBL7438482 | 0.84 | ITGB3 (0.49) | ITGB3ITGA2BF2F7F3 | |
| Hydrochloric Acid SCHEMBL6701607 | 0.83 | ITGB3 (0.43) | ITGB3ITGA2BF2F7F3 | |
| SCHEMBL6702744 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BF2 | |
| SCHEMBL3894297 | 0.83 | ITGB3 (0.51) | ITGB3ITGA2BF2 | |
| SCHEMBL6702721 | 0.83 | F2 (0.41) | ITGB3ITGA2BF2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220148-A1 | 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, LTB4R, ITGB4 | ITGB3 23/4885ITGA2B 21/4885F2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.